Compare UK & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UK | VIVS |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | China | United States |
| Employees | 42 | 9 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.5M |
| IPO Year | N/A | N/A |
| Metric | UK | VIVS |
|---|---|---|
| Price | $2.05 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.2K | ★ 4.5M |
| Earning Date | 03-24-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.43 |
| 52 Week High | $5.90 | $5.30 |
| Indicator | UK | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 18.88 |
| Support Level | $1.92 | N/A |
| Resistance Level | $2.22 | $2.21 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 28.57 | 0.72 |
Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has two operating segments: Workspace membership, and Other services. The Workspace membership segment generates the majority of the company's revenue.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.